Aerovate Therapeutics, INC Form 4 insider transactions

Mark Eisner, a Director at Jade Biosciences, Inc., acquired stock options for 47,675 shares of common stock.

Director Christopher W. Cain was granted 34,843 stock options in Jade Biosciences, Inc. as part of his service arrangement.

Director Eric Dobmeier was granted 34,843 stock options in Jade Biosciences, Inc. as part of a standard equity compensation arrangement.

Director Lawrence Otto Klein was granted 34,843 stock options in Jade Biosciences, Inc. as part of his compensation.

Director Erin Lavelle was granted 34,843 stock options in Jade Biosciences, Inc. as part of a standard equity compensation arrangement.

Fairmount Funds Management and associated directors were granted 34,843 stock options in Jade Biosciences, Inc.

Jade Biosciences' Chief Financial Officer, Bradford D. Dahms, received grants of restricted stock units and stock options, aligning executive incentives with long-term company performance.

Jade Biosciences' Chief Legal Officer, Elizabeth Balta, received 28,125 restricted stock units and options to purchase 168,750 shares.

Jade Biosciences, Inc. CEO Tom Frohlich received 78,750 restricted stock units and options to purchase 472,500 shares, aligning his incentives with long-term shareholder value.

Jade Biosciences, Inc. disclosed equity grants to Chief Scientific Officer Andrew James King, including restricted stock units and stock options.

Fairmount Funds Management and affiliated entities acquired over 1.3 million common shares and 855,000 pre-funded warrants in Jade Biosciences via a private placement.

Jade Biosciences, Inc. Chief Financial Officer, Bradford D. Dahms, has been granted stock options to purchase 526,000 shares of common stock with a vesting schedule tied to continued service.

Tom Frohlich, CEO of Jade Biosciences, recently purchased 6,000 shares of the company's common stock at a price of $7.4 per share.

Fairmount Funds Management, along with related entities and individuals, reports acquiring stock options in Jade Biosciences, Inc.

Director Erin Lavelle reports acquisition of stock options in Jade Biosciences, Inc. on April 29, 2025.

Director Lawrence Otto Klein acquired options to purchase 23,017 shares of Jade Biosciences common stock on April 29, 2025.

Christopher W. Cain, a director of Jade Biosciences, acquired stock options for 23,017 shares, which he holds on behalf of Fairmount Funds Management LLC.

Director Eric Dobmeier acquired options to purchase 23,017 shares of Jade Biosciences common stock on April 29, 2025.

RA Capital Management and related entities report changes in beneficial ownership of Jade Biosciences, Inc. common stock following a merger and reverse stock split.

Jade Biosciences presents an overview of its pipeline, highlighting JADE-001, a potential best-in-class anti-APRIL mAb for IgA nephropathy (IgAN), and its planned merger with Aerovate Therapeutics.

Aerovate Therapeutics declares a special cash dividend of approximately $2.40 per share, totaling $69.6 million, contingent on the successful completion of its merger with Jade Biosciences.

Aerovate Therapeutics is supplementing disclosures in its Form S-4 filing related to its merger with Jade Biosciences in response to stockholder lawsuits and demands, while denying any legal merit to the claims.

Jade Biosciences is advancing JADE-001, a potential best-in-class anti-APRIL mAb for IgAN, with plans for healthy volunteer data in 1H 2026 and a focus on disease-modifying treatments.

Aerovate Therapeutics anticipates declaring a cash dividend between $67.6 and $69.6 million to pre-merger stockholders in connection with its merger with Jade Biosciences.

Aerovate Therapeutics and Jade Biosciences have announced a proposed merger, subject to stockholder approval and other customary conditions.

Aerovate Therapeutics and Jade Biosciences have announced a proposed merger, subject to stockholder approval and other customary conditions, aiming to create a combined company listed on Nasdaq under the ticker symbol JBIO.

Aerovate Therapeutics and Jade Biosciences have announced a proposed merger, subject to stockholder approval and other customary conditions, aimed at creating a combined company focused on biopharmaceutical advancements.

Aerovate Therapeutics and Jade Biosciences have announced a definitive merger agreement aimed at creating a combined entity focused on advancing their respective pipelines.

Aerovate Therapeutics and Jade Biosciences announce a definitive merger agreement, with Jade merging into Aerovate in a transaction designed to allow Jade to become a publicly listed company.

Aerovate Therapeutics is set to acquire Jade Biosciences through a reverse merger, aiming to advance Jade's autoimmune disease therapies.